Thursday’s Morning Insights: Repros Therapeutics Inc (RPRX), Keryx Biopharmaceuticals (KERX), and Conn’s Inc (CONN)
Repros Therapeutics Inc (NASDAQ:RPRX) is soaring nearly 19% this morning to $2.01 following yesterday’s positive news that provided an update on the company’s EU submission for enclomiphene. The company explained that the marketing authorization application, or MAA, for enclomiphene, a drug to treat secondary hypogonadism, is on track with a decision expected by Fall 2017. The company explains that the condition is associated with obesity and is believed to be one of the most common causes of low testosterone in men. The company is conducting an on-going Phase 3 study which has demonstrated statistically significant positive results in obese men.
Keryx Biopharmaceuticals (NASDAQ:KERX) is up more than 4% this morning to $6.25 after the Baupost Group reported over a 40% stake in the company, revealed in its latest SEC filing. The Baupost Group, managed by Seth Klarman, now owns over 59 million shares of the company that specializes in treatments for renal disease. The company is most known for its pipeline product, ferric citrate, to treat iron deficiency anemia in adults with specific forms on chronic kidney disease.
According to TipRanks, 2 analysts are bullish on Keryx and 2 are neutral. The average 12-month price target for the stock is $8, marking a 33% potential upside from current levels.
Conn’s Inc (NASDAQ:CONN) is falling more than 13% this morning, down to $10.09 after the company posted disappointing earnings before market open. The company posted a fiscal first-quarter loss of $9.7 million and a loss per share of $0.31, missing analysts’ consensus of a positive EPS of $0.12. The company also lowered its 2017 outlook, revising revenue froth from mid to high single digits down to low to mid single digits. The company guides retail gross margins between 36.75% and 37.50% of total net sales, down from the previous estimate range of 37.25% to 37.75%. According to TipRanks, both analysts covering the stock are bullish with an average 12-month price target of $22.50, marking a 92% potential upside from current levels.